Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 92 posts found.

zytiga

NICE approves Janssen’s Zytiga for prostate cancer before chemo

March 21, 2016
Sales and Marketing Janssen, NICE, Zytiga, prostate cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …

News
janssen_latest_logo_on_sign_closer

Janssen’s Zytiga boosts survival in early-stage prostate cancer

March 14, 2016
Research and Development, Sales and Marketing Janssen, Zytiga, abiraterone, prednisone, prostate cancer

Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall …

News
Lynparza

AZ’s Lynparza gets prostate cancer breakthrough status

January 28, 2016
Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer

AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …

News
Exercise prostate cancer

Trial launched to test exercise as prostate cancer treatment

January 6, 2016
Research and Development Cancer Research UK, active surveillance, exercise, prostate cancer

Cancer Research UK has launched a study to determine if exercise could help men with prostate cancer, the UK’s most …

News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015
Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …

News
bayer_cross_2

NICE decision restricts Bayer’s Xofigo to select prostate cancer patients

November 19, 2015
Research and Development, Sales and Marketing Bayer, NICE, prostate cancer

NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …

News
zytiga

New cancer medicines approved in Scotland, available via NHS

October 12, 2015
Sales and Marketing Scottish Medicines Consortium, Zytiga, abiraterone acetate, prostate cancer

The Scottish Medicines Consortium (SMC) has today recommended Janssen’s Zytiga (abiraterone acetate) for use before chemotherapy in men with advanced …

News

Dendreon wins Provenge authorisation

September 19, 2013
Research and Development, Sales and Marketing Dendreon, Provenge, prostate cancer

News
bms

Yervoy setback in prostate cancer

September 16, 2013
Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer

News

Prostate cancer drug Xtandi gets nod

April 26, 2013
Sales and Marketing Xtandi, Zytiga, prostate cancer

Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …

News

Dendreon slashes staff and closes facility

July 31, 2012
Manufacturing and Production, Sales and Marketing Dendreon, M&P, Provenge, prostate cancer

Cancer vaccine specialist Dendreon has said it will slash 600 jobs and close one of its three manufacturing facilities in …

News
screen_shot_2012-07-05_at_11

New chairman of the board for Dendreon

July 5, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dendreon, Provenge, johnson, prostate cancer

Dendreon has announced that its president and chief executive John Johnson has assumed the additional title of chairman of the …

Appointment
Zytiga image

Price cut sways NICE on Zytiga

May 16, 2012
Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer

NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance.  In its final guidance, the watchdog is recommending …

News

UK government invests in new radiotherapy treatment

April 16, 2012
Sales and Marketing Cancer, Photon beam therapy, Proton beam therapy, prostate cancer, radiotherapy

The government is to invest £250 million in a cutting-edge radiotherapy treatment that should benefit 1,500 cancer patients in the …

News

Algeta to co-promote Alpharadin in US

April 12, 2012
Sales and Marketing Algeta, Bayer, prostate cancer

Algeta has exercised its option to co-promote Alpharadin for the treatment of cancer patients with bone metastases in the United …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025